.. he wasn't certain, though, how much he'd be able to work before then..
.
biohaven: "rimegepant pivotal phase 3 trial results -- conference call.".
..
.
the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid.